



Global Heart Hub

Annual Review 2025



2025: Year in Review

Our Reach, Progress and Impact at a Glance

In 2025, Global Heart Hub connected and strengthened cardiovascular patient organisations across the world, bringing lived experience into research and policy discussions, and strengthening global awareness of priority cardiovascular health issues.

Areas of focus:



Heart Failure



Heart Valve Disease




Cardiomyopathy



ASCVD



Women & Heart



Multiple
Interconnected
Chronic Conditions



Patient and Public
Involvement in
Research and
Clinical Trials



Patient
Engagement

International reach:



Worldwide reach across
international, regional &
national audiences:

320 million
opportunities to see our
annual campaigns



International awareness
campaigns delivered in

15 languages

Global training and capacity-building programmes:



2

Master Classes



4

webinars



8

workshops

91%

of participants found value
in Global Heart Hub's
training opportunities.

90%

of participants ranked
networking opportunities as
a top benefit of being part of
Global Heart Hub.

“

GHH stands out for creating meaningful space for patients – not only to be heard, but to grow, build confidence, and develop the skills they need to engage in advocacy at a level that’s right for them.

– GHH Affiliate



2025: Year in Review

Our Affiliate Community

Connecting patient organisations and strengthening collective advocacy

154

Patient Organisations

44

Countries



Global Heart Hub strengthens our work at a national level by connecting us to a global network, providing high-quality advocacy tools, and sharing insights that help shape better policy and care. - **GHH Affiliate**




Launched a new patient-focused **Clinical Research Initiative** with trusted clinical research information and a Clinical Trial Search Portal.



3
global
award wins



8
peer-reviewed publications
in leading journals



The Unite Annual Summit continues to be the largest international gathering of cardiovascular patient organisations and patient advocates.



Unite 2025 Annual Summit



200

international
delegates



from 37
countries



35

speakers



I thoroughly enjoyed the programme and the impressive lineup of panels and speakers. It was a fantastic opportunity to connect with patient leaders and advocates from all over the world.

- GHH Affiliate





Contents

Welcome message	1
About Global Heart Hub	3
Financials	4
Our Supporters	5
Collaborations	6
Company Information	6
Our Global Community	7
Clinical & Specialist Advisory Panel	9
Focus on: Heart Valve Disease	11
Focus on: Heart Failure	15
Focus on: Cardiomyopathy	17
Living with Multiple Conditions	19
Focus on: Women and Heart	21
IPEC patient-led research	27
Clinical Research Initiative	28
European Projects	29
Academy	31
Publications	33
Special Events	35
Awards	37
The GHH Team	39

A message from our Executive Director and Board Chair

Reflecting on 2025, it was once again a year of growth for our network of patient organisations, expanding our regional reach and strengthening patient engagement across the CVD landscape.

Throughout the year, we provided a platform and supported patients in their endeavours to influence the future of cardiovascular care. We delivered capacity and capability training across our global network; provided advocacy training through our Academy; launched our Clinical Research Initiative; published robust patient-led research and ensured that the lived experience was reflected across different stakeholder decision-making conversations. Collectively, we reached millions of people worldwide through disease awareness campaigns, connected patient organisations across 44 countries, and promoted patient knowledge and insight as critically important tenets to research, education and healthcare policy.

Of particular focus for Global Heart Hub throughout 2025 was women's cardiovascular health. Across the year, we worked in partnership with patients, clinicians and other stakeholders to drive meaningful change, by launching our global consensus report 'Shaping the Future for Women with Heart Valve Disease', and by having women's heart health as the theme of our Annual International Patient Organisation Summit, "Unite". Together, we elevated the voices and lived experiences of women, helping to build momentum for sex equity in research and highlighting the urgent need for earlier detection, diagnosis and guideline-directed cardiovascular care for women everywhere.

The past year served to reinforce something we have always believed – that lasting change happens through partnership. Whether championing equitable access to women's cardiovascular healthcare, strengthening patient engagement in clinical research, improving awareness of heart valve disease, heart failure or cardiomyopathy, or advocating for better integrated care for those living with multiple interconnected conditions – success is built through collaboration and a shared commitment to putting patients first.

One of the defining moments of the year was the launch of the first-ever European Cardiovascular Health Plan. This landmark achievement represents years of persistent advocacy by all stakeholders, but more importantly, strong collaboration between patient organisations and the key stakeholders across Europe. GHH is proud to have contributed to this historic milestone as a member of the European Alliance for Cardiovascular Health (EACH). We congratulate our European Affiliates who mobilised to ensure that the knowledge and insights of those living with cardiovascular disease was taken into consideration. While this is an important step forward, it signals the beginning of the next chapter, where we will work together with our community to support implementation and ensure that patients remain as key partners in shaping cardiovascular health policy across Europe. The EACH model will hopefully serve as a demonstration model for action that can be replicated in other regions of the world.

As we look ahead, we remain ambitious. Our commitment is unwavering: to continue strengthening the global cardiovascular patient community, amplifying the voice of lived experience, generating patient-led and patient-relevant evidence, influencing policy and ensuring that patients are recognised as equal partners in cardiovascular healthcare worldwide.

We are nothing without our extraordinary community. To our affiliate patient organisations; patient advocates; clinician, academic and research partners; our funders and supporters – thank you. Your passion, expertise and commitment continues to inspire and strengthen our collective mission to improve the lives of people living with or affected by cardiovascular disease.

Thank you for being part of this journey. Together, we are creating lasting change, and together we will continue to build a healthier future for all of us.



Neil Johnson
Executive Director



Kevin O'Reilly
Chair - Board of Trustees

A global voice for the lived-experience of cardiovascular disease



About Global Heart Hub

Global Heart Hub (GHH) is the first global non-profit organisation established to provide a voice for those living with, or affected by, cardiovascular disease (CVD). We are an alliance of heart patient organisations, endeavouring to create a unified global voice for those living with or affected by heart disease.

Mission

Our mission is to create and unite a global cardiovascular patient community to advocate for the best possible outcomes for people living with heart disease.

Vision

Our vision is to be the leading voice for the needs of heart patients globally, ensuring that they are equal stakeholders in cardiovascular healthcare.

Goals

- ♥ To understand the global landscape of CVD patient organisations and provide resources and support to strengthen their capacity and capability for patient advocacy.
- ♥ To represent the global CVD community on global and regional platforms as an equal stakeholder along with clinical stakeholders, and decision-makers in healthcare strategy.
- ♥ To identify pressing issues for the cardiovascular patient community and develop and advocate for innovative solutions at global, regional and national levels.



Financials

As a non-profit organisation, GHH is committed to efficient and effective use of resources. The financial management of the organisation ensures all income is utilised for the purposes for which it was received. GHH is governed by a board of voluntary non-executive directors. The board oversees the governance of the organisation and each year GHH undergoes an independent audit and files reports and accounts with the Irish companies' registration office and the Irish charity regulator.

2025 Income

In 2025, GHH received funding from 20 corporate supporters across the Pharma and MedTech industry sectors. Engagement with industry is executed under written contracts to ensure ethical and transparent collaboration where at all times our sole objective is what's best for patients and their carers.

All corporate contracts clearly and transparently specify what the funding supports. We maintain complete autonomy in the execution of all our activities and programmes and retain full editorial control of all our content development, including publications. As a patient organisation promoting cardiovascular health, we do not accept any funding from companies producing products deemed harmful to health.

In 2025, GHH participated in three EU-funded, multi-year research projects:


- READI (Research in Europe and Diversity Inclusion)
- HEU-EFS (Harmonised Approach to Early Feasibility Studies)
- RESIL-CARD (Healthcare Resilience)

Additionally, GHH was approved to participate in two further EU projects, Hospital@Home and COMPASS, both of which are scheduled to commence in 2026.

2025 Expenditure

Total Expenditure: €3.3M+

●	Capability Building	28%
●	Evidence Generation – Patient led Research	21%
●	Advocacy Training	9%
●	Disease Awareness	11%
●	Patient Stakeholder Engagement	4%
●	Governance & Management – HR, Finance, Communications & IT	27%



Our Supporters

Our work throughout the past year has been funded through multi-industry support.

We believe that ethical and transparent collaboration between industry and patient organisations contributes to valuable and important healthcare discussions, which ultimately lead to improved outcomes for patients. We undertake to always disclose the names of all our industry funders; seek support from multiple funders (to avoid real or perceived exclusive relationships); and only work with those companies who abide by our code of conduct on patient and industry engagement.



Edwards



Collaborations

GHH is proud to collaborate with:



Company Information

GHH is a non-profit organisation, registered in Ireland as a company limited by guarantee and as a charitable organisation.

Board of Trustees:

- Kevin O'Reilly, Chair - Ireland
- Susan Campbell - USA
- Pat O'Donnell - Ireland
- Susan Hennessy - Ireland
- Ellen Ross - Canada
- Richard Russell - USA

Company Secretary:

FCS Corporate Services

Executive Director:

Neil Johnson - Ireland

Registered office:

Ireland

Our Global Community

Connecting patient organisations and strengthening their reach

GHH's 154 Affiliates bring local knowledge, trusted community relationships and lived experience into a shared global network.

This enables peer learning, coordinated advocacy and stronger patient representation across national, regional and global forums.



38

Patient
Organisation
Affiliates
in North America

5

Patient
Organisation
Affiliates
in Latin America



A world map with a light purple background. The map is divided into three main regions highlighted in a darker purple: Europe, Africa & Middle East, and Asia & Australasia. Each region has a large number and text indicating the count of Patient Organisation Affiliates. Europe has 81, Africa & Middle East has 15, and Asia & Australasia has 15.

81

Patient
Organisation
Affiliates
in Europe

15

Patient
Organisation
Affiliates
in Africa
& Middle East

15

Patient
Organisation
Affiliates
in Asia
& Australasia

Clinical & Specialist Advisory Panel

Strengthening the evidence behind patient advocacy

GHH's Clinical and Specialist Advisory Panel (CSAP) is a group of leading global experts, representing interdisciplinary fields of CVD, who support GHH in helping to ensure that evidence-based knowledge underlies our efforts to achieve the best possible outcomes for those living with heart diseases.

We are honoured to announce that Prof Sandra Lauck and Prof Vijay Kunadian joined our CSAP during 2025.

Prof Sandra Lauck

As an advanced practice nurse with expertise in the innovative management of valvular heart disease and the promotion of multidisciplinary care, Prof Lauck brings a wealth of experience to GHH. Her program of research focuses on the integration of patients' perspectives in health services, the development of clinical processes to support advances in cardiac care and the promotion of cardiovascular nursing.

Speaking about her new role with GHH, Prof Lauck said, "I am honoured and excited to join the CSAP of the GHH. This is a unique opportunity for me to contribute to strong partnerships between people with lived experience of heart disease, clinicians, researchers and policymakers to advance cardiovascular care". Prof Lauck is a champion

of patient-centred care and the contributions that nurses make to optimise outcomes and the delivery of healthcare. She holds the St. Paul's Hospital Professorship of Cardiovascular Nursing at the University of British Columbia and is currently an Associate Professor at the UBC School of Nursing and a nurse clinician scientist at the Heart Centre at St. Paul's Hospital.

Prof Vijay Kunadian

Prof Kunadian is a Professor of Interventional Cardiology holding a Personal Chair at Newcastle University and Honorary Academic Consultant Interventional Cardiologist Freeman Hospital, Newcastle upon Tyne, UK. She has an international reputation in interventional cardiology and cardiovascular research and has championed diversity in her specialty as a role model (only 5% of interventional cardiologists are female in the UK, <1% are clinical academics/researchers), and the first female interventional cardiologist to hold a University Personal Chair.

Prof Vijay Kunadian is recipient of the UK Department of Health National Clinical Excellence Award. She is National Cardiovascular Specialty Group Lead, UK NIHR (National Institute for Health and Care Research) Research Delivery Network. She is the British Cardiovascular Intervention Society Research and Development Working Group National Lead and Council Member.

[Learn more: globalhearthub.org/about/advisory-panel](https://globalhearthub.org/about/advisory-panel)



Pictured: Members of the GHH Team, Board and CSAP at the 2025 Unite Summit. GHH held a strategic meeting with the CSAP members attending Unite, along with members of the Board and Team.

**We are consistently impressed
by Global Heart Hub's innovation,
growth and unwavering commitment
to patient-led advocacy.**

– GHH Affiliate



Focus on: Heart Valve Disease

Global Roadmap to Improve Care for women with HVD

In September, GHH, in collaboration with our knowledge partner EngageMinds HUB at Università Cattolica del Sacro Cuore, launched **Shaping the Future for Women with Heart Valve Disease**, an international consensus report aimed at closing critical gaps in awareness, detection, diagnosis and care for women living with heart valve disease (HVD).


Drawing on insights from patients, clinicians, researchers and industry partners across 13 countries, the report presents **six actionable recommendations to improve the outcomes for women with HVD throughout the entire patient journey**, from inclusion of more women in research to earlier access to diagnosis and personalised treatment.

HVD is a common health condition worldwide, being recognised as the next cardiac epidemic, in part related to the increasing ageing population. Yet, as the report highlights, women are frequently diagnosed late, misdiagnosed or excluded from critical clinical trials. The recommendations set out in the roadmap address these gaps head-on, urging global and local action from patient advocates, the clinical community, policymakers and healthcare systems.

The consensus was shaped through a multi-stakeholder roundtable, where the resulting report offers a comprehensive analysis of the sex- and gender-based barriers in the awareness, detection, diagnosis, treatment and follow-up of HVD in women, ensuring that lived experience is embedded in every recommendation.

Implementing these recommendations could help reduce healthcare costs through effective preventive actions, lower morbidity and mortality rates, and guide future investments and policies to promote early diagnosis, treatment, and healthier and better lives for women with HVD worldwide.

Learn more: globalhearthub.org/women-hvd



"I know first-hand how critical it is that women's voices and experiences are truly heard. Far too often, symptoms like breathlessness, fatigue, or dizziness are dismissed or misattributed, especially when reported by women. By embedding patient experience into clinical conversations and system change, we have the opportunity to improve early detection and diagnosis, ensure equitable treatment, and support women throughout their lives."

– Jacqueline Lewis, who lives with heart valve disease, co-chair of the international specialists' multidisciplinary roundtable and report contributor.

Patient Network in-person meeting

The HVD Patient Network gathered in Italy in June for an in-person meeting, enabling our Affiliates to connect, share experiences and map out our combined course for the future. Thank you to our Affiliates who attended from across 17 countries: Australia, Austria, Brazil, Canada, France, Germany, Ghana, India, Ireland, Italy, Japan, Mexico, Poland, Spain, Tanzania, the UK, and the USA, who continue to advocate for early diagnosis and equality of treatment for all those living with heart valve disease. Uniting our HVD community highlights the vital role patient organisations play in supporting and advancing the global patient agenda.



PCR London Valves 2025

GHH was delighted to host a session, “Learning from Lived Experience and Contemporary Evidence: Shaping the Treatment of Women with Heart Valve Disease”, at PCR London Valves on 17 November in collaboration with Heart Valve Voice UK and Heart Valve Voice Canada.

Insights from Marcia Malcolm’s lived experience with heart valve disease and learning from our latest report highlighted how real-world perspectives can drive more equitable and effective care for women.

Thank you to our panel – Prof Sandra Lauck, Marcia Malcolm, Prof Vijay Kunadian, Dr Fabien Praz, Prof Marta Sitges and Ellen Ross, for a truly inspiring discussion, and to PCR London Valves for supporting patient-centred care.



Focus on: Heart Valve Disease

Heart Valve Disease Awareness Campaign

Increasing awareness of early detection and diagnosis

GHH's 2025 Heart Valve Disease (HVD) Awareness Campaign ran from 15–21 September, with the aim to improve diagnosis, treatment and management of heart valve disease globally.

HVD is a medical condition that occurs when one or more of the four valves in our heart don't work properly. There are different ways that heart valves can stop working properly. Sometimes

valves don't fully open, so less blood gets through. Sometimes valves don't fully close, so they leak, allowing blood to flow the wrong way.

Detection of HVD involves identifying symptoms and listening to the heart with a stethoscope for a 'heart murmur' – an abnormal sound heard between the sounds of your regular heartbeat. A murmur does not always mean that there is a problem, but patients with warning signs, like a heart murmur, should be referred to a cardiologist, who will perform additional examinations to confirm the diagnosis.

[Learn more: globalhearthub.org/valveweek2025](https://globalhearthub.org/valveweek2025)

Breathless?

Tired?


Dizzy?

**Listen to
your heart**



Detecting Heart Valve Disease is simple and painless

Book a stethoscope check with your doctor today!



251 MILLION

OPPORTUNITIES TO SEE
#ValveWeek25

MESSAGE ACROSS PRINT, SOCIAL AND DIGITAL COVERAGE



Coverage

Translated across



15

Languages

Driven by patient organisations
and supporters across



21

Countries

Heart Valve Disease is *Common, Serious,* but **Treatable.**

Detecting it is as simple
as a stethoscope check.

Book yours today!



Focus on: Heart Failure

Heart Failure Awareness Campaign

Building understanding of heart failure and its connected conditions.

GHH's 2025 Heart Failure Awareness Campaign focused on "Heart Failure and Connected Conditions - The Whole Story". The campaign raised awareness of heart failure and the critical role connected conditions, such as diabetes, kidney disease, obesity and high blood pressure, play in its onset, progression and management. Too often overlooked, these interconnected conditions are essential to understanding the full impact of heart failure on patients' lives.

More than **60 million** people worldwide live with heart failure – a progressive condition that, when detected and managed early, can be treated effectively. Despite this, heart failure remains one of the leading causes of premature death globally.

The 2025 campaign, led by the Heart Failure Patient Network, ran from May to December, bringing together patients, carers, healthcare professionals and policymakers to highlight the complex reality of living with heart failure.

**THE WHOLE
STORY OF
HEART FAILURE
INCLUDES OTHER
CONNECTED
HEALTH
CONDITIONS.**



Heart Failure:
The Whole Story

The campaign helped patients, carers, health professionals and policymakers recognise that heart failure cannot be addressed in isolation from diabetes, kidney disease, obesity and high blood pressure.

[Learn more: globalhearthub.org/heart-failure-awareness-2025](https://globalhearthub.org/heart-failure-awareness-2025)

The
WHOLE STORY
of Heart Failure

affects the
WHOLE BODY



Heart Failure:
The Whole Story

**Heart Failure
can be managed.
Heart failure
can be controlled.**

Understanding the whole story of heart failure can help you live the life you've always wanted.



Heart Failure:
The Whole Story

48

MILLION

OPPORTUNITIES TO SEE

#HeartFailure25

MESSAGE ACROSS PRINT, SOCIAL AND DIGITAL COVERAGE



Coverage

Translated across



16

Languages

Driven by patient organisations
and supporters across



22

Countries

Patient Network in-person meeting and training

The **Heart Failure Patient Network** met in the United Kingdom in September for an in-person meeting, enabling our Affiliates to connect, share experiences and plan our activities for the future. Discussions focused on key priorities in heart failure care and advocacy, alongside dedicated training in strategic policy advocacy delivered by the International Centre for Governance and Policy. The meeting combined collective priority-setting with practical capacity building, equipping members with approaches they could apply in their own national advocacy and policy engagement.

Thank you to our Affiliates who attended from across **11 countries** including Austria, Canada, Estonia, France, Germany, Poland, Portugal, Lithuania, Ireland, the UK and the USA.



Focus on: Living with Multiple Conditions

Unite for Change: A Call to Transform Cardiovascular Care for People Living with Multiple Conditions Worldwide

In May, GHH launched its transformative report, ***Unite for Change: Transforming Cardiovascular Care for People Living with Multiple Conditions***, a policy roadmap built on five key joint asks for integrated, equitable and people-centred care, advocating to drive change and transform cardiovascular care for people living with Multiple Interconnected Chronic Conditions (MICC). The report is the output of the 2024 Unite Summit.

CVD, the world's leading cause of death, rarely exists in isolation. Millions globally are living with Multiple Interconnected Chronic Conditions such as diabetes, stroke, chronic kidney disease, liver disease and obesity. Yet, health systems remain ill-equipped to support them. Addressing the complexities of managing connected conditions requires a fundamental shift towards integration, collaboration and people-centred care. Improving detection, diagnosis and care coordination can ensure more responsive systems and meaningful impact for people managing multiple conditions.

Despite advancements in healthcare, people living with Multiple Interconnected Chronic Conditions continue to face significant barriers to effective, coordinated and people-centred care. A survey conducted during the event revealed that 88% of participants believed poorer outcomes for people living with MICC were largely due to a lack of integrated care and ineffective communication between healthcare providers.

People with lived experience must navigate complex, disconnected healthcare systems alone, with no clear point of contact to guide them. The absence of care coordinators and structured patient pathways leads to redundant testing, conflicting medical advice and poor continuity of care.



Transforming healthcare requires collective action from policymakers, healthcare professionals, patient organisations, industry and academia. Each stakeholder has a vital role to play in bridging systemic gaps and ensuring that people-centred solutions become a reality.

GHH is calling on all healthcare stakeholders to take immediate action to embed these reforms into national and international health strategies, including the European Cardiovascular Health Plan.

[Learn more: globalhearthub.org/unite-for-change-report](https://globalhearthub.org/unite-for-change-report)

The Unite for Change report presents a clear policy roadmap built on five key joint asks, shaped by people with lived experience and supported by global health leaders:

1. Multidisciplinary Care & Navigation

Ensuring coordinated, specialist-led teams and patient navigation support.

2. Early Detection & Community Screening

Scaling proactive, accessible screening for high-risk communities.

3. Innovation & Digital Health Access

Accelerating the adoption of AI, telehealth and integrated digital tools.

4. Equity in Care

Closing gender, geographic and socio-economic gaps in diagnosis and treatment.

5. Prevention, Empowerment & Mental Health Integration

Embedding mental health and patient advocacy into care models.



Focus on: Cardiomyopathy

Cardiomyopathy Awareness Campaign

Supporting earlier recognition and diagnosis

GHH's 2025 Cardiomyopathy Awareness Campaign "Think Cardiomyopathy" focused on the impact of cardiomyopathy and the importance of recognising the signs and symptoms and knowing your family history.

Cardiomyopathy is the leading cause of sudden cardiac death in young people, a major cause of heart failure and the main reason for needing a heart transplant. It is a disease of the heart muscle that can occur at any age and can be passed down genetically.

Often underdiagnosed, misdiagnosed, or diagnosed too late, the consequences of cardiomyopathy can be very serious. If untreated, cardiomyopathy can weaken the heart, leading to complications and more serious conditions.

[Learn more: globalhearthub.org/cardiomyopathy-awareness-2025](https://globalhearthub.org/cardiomyopathy-awareness-2025)



It affects around
1 in 250 people,
but some are at more risk
than others

This campaign was made possible by a sponsorship grant from Bristol-Myers Squibb and Cytokinetics. Sponsors had no input or involvement in the design, development or content of the campaign.

Cardiomyopathy
often runs in families,
passed down from one
generation to the next.



Cardiomyopathy is a leading
cause of **sudden cardiac death**,
a major cause of **heart failure**
and the **main reason for**
heart transplants.

20 MILLION

OPPORTUNITIES TO SEE

#ThinkCardiomyopathy

MESSAGE ACROSS PRINT, SOCIAL AND DIGITAL COVERAGE



Patient Network in-person meeting

GHH was proud to host a Cardiomyopathy Patient Network meeting in Spain in August, bringing together 22 participants from 15 countries. We are deeply grateful to our network for their unwavering dedication and ongoing efforts to promote early diagnosis and equal treatment access.

This meeting underscored the crucial role that patient organisations have in driving and influencing the global patient agenda. Discussions focused on moving from tokenism to meaningful patient partnership in research,

understanding and using cardiomyopathy guidelines as a tool for collective stakeholder action, and turning patient experience data into credible evidence for advocacy and system change. The meeting strengthened the Network's focus on ensuring that lived experience is not simply heard, but actively shapes research, care and decision-making.

This meeting was supported by Bristol Myers Squibb & Alnylam Pharmaceuticals.

Focus on: Women and Heart

Women & Heart Patient Network

Cardiovascular disease is the leading cause of death among women – yet women continue to experience late, missed and misdiagnosis of heart disease – often compounded by fragmented care.

The Women & Heart Patient Network brings together patient organisations to advocate for action to be taken to correct disparities and improve the lives and well-being of women with cardiovascular disease, their families and their communities.

Throughout 2025, GHH worked with women living with CVD, Affiliates, clinicians and partners to expose persistent gaps in research, recognition, diagnosis and care and to define practical priorities for change.

EuroPCR 2025

In May, GHH hosted a powerful session at EuroPCR in Paris on 22 May, 'Redefining the Red Flags: Early Detection of Myocardial Infarction in Women'. The session highlighted the story of Clodagh O'Bric, a young woman who survived myocardial infarction. A critical gap remains in recognising and addressing the unique presentation of heart attacks in women; sex-specific approaches are needed.

Thank you to our panellists Prof Martine Gilard, Prof Alaide Chieffo, Clodagh O'Bric, Dr Marko Noc, Aištė Štaraitė and Dr Marie-Christine Iliou for sharing their expertise, insights and lived experience, and special thanks to EuroPCR for supporting this important conversation on women's cardiovascular health.



Her Final Search Campaign

GHH and our Irish Affiliate Croí, the Heart and Stroke Charity, partnered to launch the 'Her Final Search' campaign in 2025, educating about the unique symptoms of heart attack in women.

Through a series of videos distributed across social media depicting final online symptom searches of women who died of CVD/heart attack, this initiative educated the public on the specific symptoms that women may experience differently from men, such as jaw, neck and back pain, to help more people know when to seek help.

The campaign builds upon the poignant story of Lynn Witham, a 60-year-old woman from the UK, who was found dead next to a tablet where she had been trying to Google signs of a heart attack.

[Learn more: www.croi.ie/heart/women-at-heart](http://www.croi.ie/heart/women-at-heart)

**This was Linda's*
final search.**



🔍 Jaw ache, feel sick

**Don't let it be yours.
Get to know the symptoms
of heart attack in women,
before it's too late.**

*Fictional person based on a real story

IPEC2

In 2025, GHH launched a new patient-led qualitative research project on women's experiences with cardiovascular disease called IPEC2 (Insights & Patient Experiences with CVD).

IPEC2 will collect patient experience data from approximately 300 women in 8 countries. It builds on prior work conducted in Australia, Brazil and the United States. The study will include women with cardiovascular conditions such as ASCVD, elevated LDL-C, elevated LP(a), heart valve disease and cardiomyopathy.

The study is being guided by a Steering and a Review Committees, comprised of people with lived experience, patient organisation leaders and international clinical experts. Results will be shared in 2026.

Study objectives:

- Explore women's experiences, awareness and recognition of cardiovascular symptoms;
- Identify pathways and barriers to cardiovascular healthcare; and
- Assess the burden of managing cardiovascular disease on women's lives.

[Learn more: globalhearthub.org/ipec2](https://globalhearthub.org/ipec2)



Unite Annual Summit 2025

2-4 NOVEMBER 2025 • DUBLIN, IRELAND

Women's Cardiovascular Health

The focus for the 5th Unite Annual Summit was on Women's Cardiovascular Health.

CVD is the leading cause of death in women worldwide. Too often, women's symptoms are misinterpreted or overlooked due to a lack of awareness about how CVD presents differently in women. Urgent global action is required to stop this and improve the screening, diagnosis and treatment journey for women with CVD.

GHH would like to acknowledge and extend our appreciation to our partners in women's cardiovascular health, especially the members of Global Heart Hub's Women & Heart Patient Network.

Unite for Action

The 2025 Unite Summit featured 35 incredible speakers across its programme, exploring the challenges and issues of:

- ♥ late, missed and misdiagnosis of CVD in women;
- ♥ under-representation of women in CVD clinical trials;
- ♥ under-research of female-specific risk factors and heart conditions.

By uniting experts from around the world in women's cardiovascular health, from patients with lived experience to clinicians, policymakers and key opinion leaders, we endeavour to turn insight into action and improve treatment and care for women living with CVD.

The health disparities between women and men with CVD are an urgent, global problem that has been repeatedly ignored and dismissed for too long. Women with CVD must no longer be overlooked but instead supported, informed and empowered at every step of their journey.



200
Delegates

37
Countries

35
Speakers



**Action must be taken to correct these disparities
and improve the lives and well-being of women
with cardiovascular disease.**

**Neil Johnson,
Executive Director,
Global Heart Hub**

In 2025, #GHHUnite reached over
400k
organic impressions on social media
during the three-day event



We all have an important role to play in educating and informing stakeholders, and it is essential to collaborate to ensure the best possible future for women living with cardiovascular disease.

**Joanna Ten-Kate,
Community Engagement Manager,
Global Heart Hub**



100% of attendees
rated the event as excellent
or good in 2025!



IPEC Patient-Led Research

Exploring The Results: Insights From Patients Living With Elevated Cholesterol (IPEC) Study

GHH's patient-led research, the IPEC Study (Insights from Patients living with Elevated Cholesterol), is a transnational qualitative study, conducted across Australia, Brazil and the United States. The study explored the lived experiences of individuals diagnosed with high levels of LDL-C.

This patient-led research spotlights the urgent need for improved communication, education and personalised care in cholesterol and CVD management. It also highlights the value of patient experience data and patient insights research.

[Report available here: globalhearthub.org/ipec](https://globalhearthub.org/ipec)


IPEC Presentations

In 2025, GHH presented findings from the patient-led *Insights from Patients Living with Elevated Cholesterol* (IPEC) Study including at the European Society of Cardiology Preventive Cardiology Congress and ACNAP Congress 2025.

IPEC Study Published in Global Heart Journal

GHH's IPEC Study was published in the Global Heart Journal, the official scientific journal of the World Heart Federation.

[Read here: globalheartjournal.com/articles/10.5334/gh.1441](https://globalheartjournal.com/articles/10.5334/gh.1441)



Clinical Research Initiative

Global Heart Hub launches new patient-focused Clinical Research Initiative

GHH has launched a new Clinical Research Initiative with trusted clinical research information and a Clinical Trial Search Portal to empower the CVD patient community with the knowledge, tools and opportunities to be active participants in shaping the future of cardiovascular care.

The GHH Clinical Research Initiative aims to make cardiovascular health research more accessible and relevant. “Patients are essential partners in research. Clinical trials are a critical step in advancing treatment, improving outcomes and saving lives, but only succeed when patients are informed, involved and participate,” says Neil Johnson, Executive Director, GHH.

When patients are engaged in research, the outcomes are better – a reduced burden of disease, with treatments which meet the real-life needs of the community they serve. With input from the patient community, GHH has included trusted information about clinical research on our website, and developed a user-friendly Clinical Trial Search Portal, adapted to local languages and tailored to feature CVD trials available in individual countries.

[Visit: \[globalhearthub.org/clinical-research-and-trials\]\(https://globalhearthub.org/clinical-research-and-trials\)](https://globalhearthub.org/clinical-research-and-trials)



European Projects



The European Alliance for Cardiovascular Health (EACH) Cardiovascular Health Summit

On 10 December, the European Alliance for Cardiovascular Health (EACH) opened the EACH Cardiovascular Health Summit in Brussels, bringing together policymakers, clinicians, patients, researchers, and industry leaders at a decisive time for cardiovascular health in Europe. With the launch of the EU Cardiovascular Health Plan, the Summit provided a timely forum to reflect on the work that has led to this milestone and to begin shaping the next steps for implementation and investment across Member States.

CVDs remain the leading cause of death and disability in the EU, affecting over 62 million people and costing the European economy more than €282 billion annually. This burden underscores the urgent need for coordinated action at both European and national levels to advance prevention, strengthen early detection, and improve access to high-quality care. The Summit featured a keynote address from

Olivér Várhelyi, European Commissioner for Health and Animal Welfare, who spoke about the Commission's vision for cardiovascular health and the opportunity presented by the forthcoming EU Cardiovascular Health Plan.

Speakers also underscored ongoing inequalities across Europe, gender gaps in diagnosis and treatment, and the importance of integrating mental health into cardiovascular care.

A special patient panel, Patient Voices in Action: How Lived Experience Can Guide a Transformative EU Cardiovascular Health Plan, included speakers Francesca Musso (HCM Patient Foundation, GHH), Kostas Tagkalos (International Diabetes Federation Europe), Diana Wong Ramos (Portugal AVC, Stroke Alliance For Europe (SAFE), GHH Affiliate) and Marc Rijken (Global Lp(a) Taskforce, FH Europe Foundation).

Together, we can reduce the burden of CVDs, improve quality of life, and ensure that every person in Europe has the opportunity to live longer, healthier lives.

Launch of the first-ever EU Cardiovascular Health Plan

On 16 December 2025, the European Commission launched the first EU Cardiovascular Health Plan, known as the Safe Hearts Plan. The Plan made cardiovascular health a shared European priority and set out measures to strengthen prevention, early detection, treatment and care across Member States.

GHH welcomed this important milestone after advocating alongside its EU Affiliates and partners in the European Alliance for Cardiovascular Health for a comprehensive European approach. Together, we highlighted the need to recognise patients as essential stakeholders in cardiovascular policy.

GHH will now work with our EU Affiliates to support national implementation. We will advocate for national cardiovascular health plans that reflect each country's context, culture and lived experience and meaningfully involve patients in their development and delivery.

READI Project Launches to Enhance Patient Representativeness and Inclusion in European Clinical Research

READI (Research in Europe and Diversity Inclusion) is a six-year IHI project, uniting 73 partners across 18 countries with the shared goal of making clinical research in Europe more inclusive and representative. The project aims to address long-standing disparities by focusing on the inclusion of underserved and underrepresented communities – such as women, ethnic minorities, older people, LGBTQ+ individuals, and those from diverse socioeconomic backgrounds – in clinical studies.

By breaking down barriers and setting new standards for diversity and equity in clinical trials, READI aims to generate meaningful scientific evidence that better reflects the reality of European populations. This approach not only improves health outcomes for underserved groups, but enhances the overall quality and reliability of clinical research for everyone.

As a partner in the IHI READI consortium, GHH leads efforts to embed the patient voice in cardiovascular research and policy. The

organisation contributes to the design and testing of communication tools that improve health literacy and awareness among underrepresented populations, ensuring patients can make informed decisions about participation in clinical studies. Through its extensive patient networks, GHH also supports the co-creation of educational resources, promotes gender equity in recruitment, and helps translate READI's inclusive research principles into real-world cardiovascular contexts.

Global Heart Hub joins the OnHOME Alliance!

GHH has become a member of the Order and Home Delivery of Medicines (OnHOME) Alliance. This alliance unites patient organisations and healthcare stakeholders committed to advocating for better access to prescription medicines across Europe.

Our collective goal is to ensure that every patient has the option to order their medicines online and have them delivered directly to their doorstep by registered pharmacies.

Key Objectives of the OnHOME Alliance:

- Improve patients' access to healthcare services and medicines
- Support chronic and rural patients
- Ensure preparedness for health threats

As part of this alliance, GHH is actively working towards policy changes that will expand digital access to healthcare and medicines throughout Europe. We believe it is crucial to remove unnecessary barriers and prohibitions that hinder patients from accessing the care they need, especially those with mobility issues or living in remote areas.

RESIL-Card

RESIL-Card is an EU4Health funded project dedicated to enhancing the resilience of European healthcare systems in providing cardiovascular care. Global Heart Hub supports the work of the consortium in its efforts around communication and dissemination.

The project aims to develop and implement a protocol-based tool, launching in 2026, enabling cardiovascular stakeholders assess and address the gaps in care systems, ensuring continuity during crises.

Academy

Strengthening advocacy capacity across the GHH community

The GHH Academy supports the global heart patient community to develop advocacy capacity and capability.

Key activities across 2025 included:

Empower Webinars

- ♥ Beyond the Physical: Social and Emotional Wellness Strategies for Stroke and Heart Recovery
- ♥ Shaping the Future for Women with Heart Valve Disease
- ♥ Heart Failure & Its Connected Conditions: Understanding Risk & Early Detection
- ♥ Cholesterol: Types, Effects and its Role in CVD

Master Classes for Advanced Training

- ♥ 8-10 July: Advocacy, Stakeholder Engagement & Health Technology Assessment, led by the SDA Bocconi School of Management
- ♥ 4-6 Sept: Strategic Advocacy and Communications, led by the International Centre for Governance and Policy

GROW Virtual Workshops for Patient Organisations and Patient Advocates

- ♥ Strategic Planning and Governance
- ♥ Planning & Launching New Initiatives and Programmes
- ♥ Keep, Grow, Reflect – Managing, Evaluating & Reviewing Volunteer Engagement
- ♥ From Hello to Help – Recruiting and Supporting Volunteers
- ♥ Laying the Groundwork for Volunteer Success
- ♥ Adapting to a Changing Social Media Landscape
- ♥ Governance & Fundraising
- ♥ Optimising Sources for Successful Fundraising

Strengthening the voice of the cardiovascular disease patient community




Publications

During the year, Global Heart Hub published two major reports:


Shaping the Future for Women with Heart Valve Disease

A global consensus report that highlights the urgent and unmet needs of women living with heart valve disease (HVD), a growing yet under-recognised cardiovascular condition.



Unite for Change

Transforming Cardiovascular Care for People Living with Multiple Interconnected Chronic Conditions – A unified global, patient-led report created collaboratively by 165 delegates across 34 countries, calling for urgent action and a clear roadmap to transform outcomes for people living with cardiovascular and interconnected conditions worldwide.



In addition, Global Heart Hub achieved eight peer-reviewed publications:

A Manifesto from Global Heart Hub for early detection and diagnosis of cardiovascular disease

Pinto F J, Harding E, Fenton O, A Manifesto from Global Heart Hub for early detection and diagnosis of cardiovascular disease, *European Heart Journal*, Volume 46, Issue 4, 21 January 2025, Pages 339–340, <https://doi.org/10.1093/eurheartj/ehae455>

Global Heart Hub report: ‘Unite for change in transforming cardiovascular care for people living with multiple conditions’

Jones J, Collis P, Ten-Kate J, Hendriks J M, Global Heart Hub report: ‘unite for change in transforming cardiovascular care for people living with multiple conditions’, *European Journal of Cardiovascular Nursing*, 2025;, zvaf193, <https://doi.org/10.1093/eurjcn/zvaf193>

Highlights from the Manifesto on Early Detection and Diagnosis of Cardiovascular Disease: The Role of Laboratory Tests and Emerging Technologies

Gruson D, Peranio C, Štaraitė A, Hobbs R, Borch-Johnsen K, Ademi Z, Uchmanowicz I, Johnson N. Highlights from the Manifesto on Early Detection and Diagnosis of Cardiovascular Disease: The Role of Laboratory Tests and Emerging Technologies. *EJIFCC*. 2025 Feb 28;36(1):9–11. PMID: 40061066; PMCID: PMC11886626. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11886626/>

Highlights from the Manifesto on the Health Economics of Cardiovascular Disease Prevention

Ademi Z, Rodda S E, Vivoda K, et al. Highlights from the Manifesto on the Health Economics of Cardiovascular Disease Prevention. *PharmacoEconomics* 43, 1281–1292 (2025). <https://doi.org/10.1007/s40273-025-01537-5>

Addressing cardiovascular health disparities: global perspectives from the patient community

Padilla Cabrera K, et al. The Lancet Regional Health – Europe, Volume 56, 101404. [https://www.thelancet.com/journals/lanepa/article/PIIS2666-7762\(25\)00196-6/fulltext](https://www.thelancet.com/journals/lanepa/article/PIIS2666-7762(25)00196-6/fulltext)

Experiences of People Diagnosed with High Levels of LDL Cholesterol and Atherosclerotic Cardiovascular Disease: Results from a Multinational Qualitative Study

Johnson N, Vandigo J, et al. *Global Heart*. Year: 2025, Volume: 20 Issue: 1, Page/Article: 63, DOI: 10.5334/gh.1441. <https://globalheartjournal.com/articles/10.5334/gh.1441>

A path forward for the implementation of shared decision-making in valvular heart disease: global joint recommendations from clinicians, patients and researchers

Lauck S B, Gulati M, Lewis, K B et al. A path forward for the implementation of shared decision-making in valvular heart disease: global joint recommendations from clinicians, patients and researchers. *Health Res Policy Sys* 23, 136 (2025). <https://doi.org/10.1186/s12961-025-01393-x>

The patient perspective: involvement of patients in translational research and clinical investigations

Bragagnolo M, Zeisl Y, Louati C, de Luca EC. *Orthop Procs*. 2025;107-B(SUPP_7):79–79. doi:10.1302/1358-992X.2025.7.079. <https://boneandjoint.org.uk/Article/10.1302/1358-992X.2025.7.079>

Special Events

February 2025

Unmet Needs in Cardiovascular Health Across Europe – Brussels

David Kelly represented GHH at a conference hosted by the Permanent Representation of the Republic of Poland to the EU. The meeting addressed unmet needs in cardiovascular health, with discussions on prevention, inequalities in access to care, digital health promotion and increased EU funding.

March 2025

DIA Europe 2025 – Basel

Marta Bragagnolo attended DIA Europe 2025 as a patient partner, representing the patient perspective at one of Europe's largest life sciences conferences. She contributed to discussions bridging policy and real-world patient experience to help ensure healthcare systems are equitable and patient-centred.

April 2025

A European Cardiovascular Health Plan: The Roadmap – EU Parliament

GHH participated in the inaugural meeting of the MEP Cardiovascular Health Group and the launch of "A European Cardiovascular Health Plan: The Roadmap." David Kelly shared his lived experience of CVD, ensuring the patient perspective was central to discussions.

May 2025

MedTech Forum 2025 – Lisbon

Marta Bragagnolo spoke at the session "A New Cardiovascular Health Plan for Europe, a Game Changer for Patients." She highlighted the importance of embedding patients and carers as equal partners in the design and implementation of the EU Cardiovascular Health Plan to ensure meaningful, patient-centred outcomes.

European Patients' Rights Day – EU Parliament

David Kelly attended a session on the benefits of health data sharing for patients, healthcare systems and research. He reinforced the importance of equitable access to health data to improve outcomes for people living with CVD.

June 2025

Fatty Liver & NCDs: A European Policy Action – European Parliament

David Kelly attended this policy event in support of the European Liver Patients' Association. We advocated for early detection, equitable access to care and stronger recognition of the link between steatotic liver disease and CVD within EU health policy.

Patient Engagement Open Forum 2025 – Baveno

Marta Bragagnolo participated in a panel focused on advancing women's health and patient-centred care. She contributed to co-creation discussions aimed at strengthening shared decision-making and improving healthcare systems to better reflect women's needs.

Amyloidosis Ireland International Conference – Derry

Joanna Ten-Kate attended the conference, engaging with patients, caregivers and healthcare professionals. We supported discussions highlighting the link between amyloidosis and cardiovascular health and reinforced the importance of patient voices in improving care.

European Orthopaedic Research Society Conference – Davos

Marta Bragagnolo presented on patient engagement in Early Feasibility Studies as part of the HEU-EFS project. She shared insights from patient consultations and the Patient Advisory Group, emphasising the value of early patient involvement in research and innovation.

July 2025

EU Health Technology Assessment Meetings – Brussels

Marta Bragagnolo represented cardiovascular patients at the HTA Stakeholder Network Meeting and the European Commission's conference on the new EU HTA Regulation. She advocated for strong patient involvement at every stage of health technology assessment implementation.

September 2025

HEU-EFS Annual Meeting – Barcelona

Marta Bragagnolo represented GHH at the annual meeting of the HEU-EFS project. She contributed to discussions on developing a harmonised EU framework for early feasibility studies and ensuring patient involvement is embedded in the roadmap for future implementation.

ICHOM 2025 – Dublin

Karen Padilla and Teresa Glynn attended ICHOM 2025. Karen presented our report, “Shaping the Future for Women with Heart Valve Disease,” during a patient engagement workshop, highlighting practical strategies for embedding patient co-development into healthcare decision-making.

October 2025

European Commission Youth Consultation on Cardiovascular Health – Brussels

Three GHH patient advocates—Chloe Greene, Francesca Musso and Aedan Kaal—participated in a European Commission consultation on the upcoming EU Cardiovascular Health Plan. They shared perspectives on prevention, support and care for young people living with CVD.

HTA Stakeholder Network Meeting – Brussels

Marta Bragagnolo represented GHH at the HTA Stakeholder Network meeting, ensuring the cardiovascular patient voice was included in discussions on implementing the EU Health Technology Assessment Regulation.

November 2025

American Heart Association Scientific Sessions – New Orleans

Joanna Ten-Kate attended AHA Scientific Sessions, connecting with affiliates and the wider community while representing GHH within the global scientific forum.

FH Europe Foundation Annual Network Meeting – Zagreb

Aisling Hennessy attended the FH Europe Foundation Annual Network Meeting in Croatia. The meeting brought together patients, caregivers, policymakers and more to reflect on progress in FH and related conditions, as well as supporting multi-stakeholder collaboration.

ISPOR Europe 2025 – Scotland

A poster titled “Patient Involvement in Health Technology Assessment: A Global Review of Practices, Purposes and Pathways” was presented by Vittoria Ardito and co-authored by Marta Bragagnolo and colleagues. The research highlighted GHH’s work advancing patient involvement in HTA globally.

“Cardiovascular Health Crisis – What Is Our Response?” – European Parliament

David Kelly attended this European Parliament event hosted by MEP Romana Jerkovic. He ensured the patient perspective was represented in discussions on reversing cardiovascular health trends in Europe.

Cardiomyopathies Matter Event – Brussels

David Kelly participated in the Cardiomyopathies Matter event, advocating for the inclusion of cardiomyopathies and inherited CVDs within the EU Cardiovascular Health Plan and supporting policy recommendations to improve diagnosis and care.

European Patients’ Forum Congress 2025 – Brussels

Marta Bragagnolo represented GHH at EPF Congress 2025. She contributed to patient-led discussions on AI, antimicrobial resistance, health equity and climate and health, strengthening patient-centred policy dialogue.

December 2025

“Bridging the Gap” Initiative Meeting – Budapest

GHH representatives attended the second meeting of the “Bridging the Gap” initiative. We worked alongside partner organisations to unify the patient voice across cardiovascular, obesity, liver, diabetes and kidney disease communities and define priority areas for collaborative action.

European Business Summits Health Summit – Brussels

Teresa Glynn spoke on the panel “The Heart of the Matter: Exposing Europe’s Cardiovascular Crisis.” She addressed equity challenges facing women with CVD, patient engagement, screening and opportunities within the new EU Cardiovascular Health Plan.

Awards

Global Heart Hub Campaign on CVD in Women Wins Two Awards

GHH is proud that our pilot awareness campaign with Croí Heart & Stroke Charity (Ireland), in partnership with Weber Shandwick, won Patient Advocacy Project of the Year and Patient Education Project of the Year Non-Pharmaceutical at the 2025 Irish Healthcare Awards, held on 4 November in Dublin, Ireland.

The campaign, “Fatal Searches – Her Final Search” used a series of powerful videos to highlight how women can experience the symptoms of a heart attack different to men.

Equally, the campaign aimed to raise awareness that heart disease is not just a man’s disease.



Most Effective Voice of the Year Award for 2024 at the World Heart Federation Awards

GHH was delighted to accept this award on behalf of the cardiovascular patient organisation and patient advocate community we represent, who are united in their commitment to highlight and address the needs of those living with or affected by heart disease.

The award recognises the united efforts of the GHH international heart patient community in 2024 across disease awareness campaigns on Cardiomyopathy, Heart Valve Disease, Heart Failure and ASCVD; policy advocacy on early detection & early diagnosis; building global collaboration through patient networks, training programmes and the annual international UNITE Summit.

The citation commends **GHH** on setting a new standard for patient-led advocacy in cardiovascular health.

Global Heart Hub Manifesto Wins Global Cardiovascular Award

GHH was honoured to be named winner of the Best Prevention category at the 2025 Global Cardiovascular Awards for our manifesto, "Achieving Early Detection and Diagnosis of Cardiovascular Disease."

Project Lead Olive Fenton and Senior Strategy & Partnerships Executive Teresa Glynn represented GHH at the ceremony, where they proudly accepted the award. Speaking about the project, Olive shared: "It is an honour to represent the cardiovascular patient voice at this prestigious event, which recognises the vital contributions of multidisciplinary key players in advancing global cardiovascular care." This award is a testament to the power of collaboration. Together, we can drive real change in the early detection and diagnosis of CVD.

In 2024 GHH united the CVD patient community with global thought leaders to create this first global manifesto calling for early detection and diagnosis of CVD: **"Achieving early detection and diagnosis of cardiovascular disease: A manifesto for change."** A huge thank you to everyone who contributed to this important manifesto. We celebrate this award with you.

The GHH Team

Celebrating the dedication, collaboration and hard work of the Global Heart Hub team throughout 2025, including:

- Neil Johnson, Executive Director
 - David Kelly, Operations Manager
 - Mary Heskin, Finance Manager
 - Manjusha Chatterjee, Head of Programs & Development
 - Karen Padilla, Networks Manager
 - Callum Ferguson, Networks Lead
 - Aistė Štaraitė, Development Executive / Network Lead – Heart Failure
 - Patricia Tiramani, Development Executive / Network Lead – Cardiomyopathy
 - Joanna Ten-Kate, Community Engagement Manager
 - Rebecca Loughlin, Community Engagement Associate
 - Aisling Hennessy, Executive Assistant and Community Engagement Associate
 - Marta Bragagnolo, EU Advocacy Manager
 - Teresa Glynn, Senior Executive, Strategy & Partnerships
 - Olive Fenton, Senior Executive, Special Projects
 - Edel Kenneally, Communications Manager
 - Karen McGarty, Senior Communications Specialist
 - Joanna Perkowska, Digital Designer (UX/UI)
 - Michael Warnock, Digital Communications Associate
- Learn more about our team: globalhearthub.org/about/about-us







FOLLOW

WWW.GLOBALHEARTHUB.ORG



[/GlobalHeartHub](https://www.facebook.com/GlobalHeartHub)



[Global Heart Hub](https://www.linkedin.com/company/global-heart-hub)



[@GlobalHeartHub](https://twitter.com/GlobalHeartHub)



[@globalhearthub_org](https://www.instagram.com/globalhearthub_org)

